Patents Assigned to AstraZeneca AB
  • (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor
    Patent number: 10961236
    Abstract: Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: March 30, 2021
    Assignee: AstraZeneca AB
    Inventors: Matthew Perry, Christian Tyrchan, Konstantinos Karabelas, Antonios Nikitidis, Mickael Mogemark, Jens Petersen, Peter Bold, Ulf Borjesson
  • Chemical compounds
    Patent number: 10961241
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: March 30, 2021
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
  • Computer system and method for generating trigger alerts to maximize interactions with healthcare providers
    Patent number: 10957435
    Abstract: A pharmaceutical company may employ a computer system that is configured to train a machine learning model for predicting a next time in the future at which a given type of treatment decision is likely to be made for a patient, use the trained machine learning model to analyze anonymized patient data for patients treated by a given health care provider (HCP) in order to predict a next time in the future at which the given HCP is likely to make a given type of treatment decision for at least one patient, and then responsively generate a trigger alert suggesting that the given HCP be visited prior to the predicted next time to deliver a message related to the given type of treatment decision, which may in turn be delivered to a target of the trigger alert.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: March 23, 2021
    Assignee: ASTRAZENECA AB
    Inventor: Kishore Kumar
  • Chemical compounds
    Patent number: 10954211
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 23, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Inducible modification of a cell genome
    Patent number: 10947559
    Abstract: The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 16, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Marcello Maresca, Mohammad Bohlooly-Yeganeh, Himjyot Jaiswal, Lorenz M. Mayr, Xiufeng Xu
  • Composition for Inhalation
    Publication number: 20210069215
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Application
    Filed: March 27, 2020
    Publication date: March 11, 2021
    Applicant: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
    Publication number: 20210047312
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 18, 2021
    Applicant: AstraZeneca AB
    Inventors: Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
  • Halo-substituted piperidines as orexin receptor modulators
    Patent number: 10894789
    Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 19, 2021
    Assignees: ASTRAZENECA AB, EOLAS THERAPEUTICS, INC.
    Inventors: Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
  • MCL-1 inhibitors and methods of use thereof
    Patent number: 10889594
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: January 12, 2021
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Wenzhan Yang, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • Therapeutic dendrimers
    Patent number: 10888624
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
    Patent number: 10882858
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising to substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: January 5, 2021
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
  • Inhibitors of phosphatidylinositol 3-kinase gamma
    Patent number: 10858355
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Mickael Mogemark, Nils Pemberton, Jens Petersen, Matthew Perry, Konstantinos Karabelas, Pavol Zlatoidsky, Rhona Cox, Christian Tyrchan
  • C-anilinoquinazoline compounds and their use in treating cancer
    Patent number: 10829479
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: November 10, 2020
    Assignee: AstraZeneca AB
    Inventors: Jason Kettle, Stuart Pearson, Martin Packer, James Smith, Tudor Grecu
  • Inhalation device for powdered drugs
    Patent number: 10828433
    Abstract: The invention refers to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when actuated by the patient.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: November 10, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Martin Herder, Gerhard Ludanek, Ingo Mett, Joachim Schmidt
  • NMDA antagonist prodrugs
    Patent number: 10815199
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: January 20, 2019
    Date of Patent: October 27, 2020
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA
    Publication number: 20200308164
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) and phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 21, 2017
    Publication date: October 1, 2020
    Applicant: AstraZeneca AB
    Inventors: Matthew PERRY, Christian TYRCHAN, Konstantinos KARABELAS, Antonios NIKITIDIS, Mickael MOGEMARK, Jens PETERSEN, Peter BOLD, Ulf BORJESSON
  • NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
    Publication number: 20200299289
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (P13K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: March 9, 2017
    Publication date: September 24, 2020
    Applicant: AstraZeneca AB
    Inventors: Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
  • Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938
    Patent number: 10772890
    Abstract: The present invention relates to the use of myeloperoxidase inhibitors (MPO) inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 15, 2020
    Assignee: AstraZeneca AB
    Inventors: Hakan Eriksson, Werner Poewe
  • [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
    Patent number: 10766905
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Orally disintegrating tablets
    Patent number: 10729655
    Abstract: The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S,2S,3R,5S)-3-[7-{[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the rapidly disintegrating oral dosage form are also disclosed.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 4, 2020
    Assignee: AstraZeneca AB
    Inventors: Farhan Abdel Karim Mohammad Al Husban, Lars Håkan Christer Glad, Jenny Malin Christina Hallstein, Andrea Jane Moir, Michael Peter Thompson